canerpaturev + gemcitabine + nab-paclitaxel

This combination drug consists of **canerpaturev** (C-REV, HF10)—a genetically modified, attenuated oncolytic herpes simplex virus type-1—combined with **gemcitabine** (a nucleoside analog antimetabolite), and **nab-paclitaxel** (albumin-bound paclitaxel, a microtubule inhibitor). Canerpaturev selectively infects and lyses tumor cells, stimulating local and systemic antitumor immune responses, including recruitment and activation of cytotoxic T lymphocytes. Gemcitabine inhibits DNA synthesis by incorporating into DNA and preventing elongation, leading to apoptosis in rapidly dividing cells. Nab-paclitaxel stabilizes microtubules, preventing cell division and promoting apoptosis, while the albumin-based delivery improves tumor penetration and accumulation via interaction with tumor stroma and possibly SPARC (Secreted Protein Acidic and Rich in Cysteine)[1][2][4][6][8]. This combination is under clinical investigation for advanced pancreatic cancer, aiming to synergize oncolytic immunotherapy and chemotherapy by enhancing tumor killing, modulating the microenvironment, and depleting tumor stroma.

Other names

nano albumin-bound paclitaxel (nab-paclitaxel)C-REVHF10HF-10HF 10canerpaturevgemcitabine